Berupipam

Berupipam
Clinical data
Other names	NNC 22-0010; NNC-22-0010; NNC220010; NNC2210; NNC-2210
Drug class	Dopamine D1 receptor antagonist
Identifiers
	IUPAC name (5S)-5-(5-bromo-2,3-dihydro-1-benzofuran-7-yl)-8-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol;
CAS Number	150490-85-0;
PubChem CID	66002;
ChemSpider	59394;
UNII	420895MAOC;
ChEMBL	ChEMBL2106005;
Chemical and physical data
Formula	C19H19BrClNO2
Molar mass	408.72 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC(=CC4=C3OCC4)Br)O)Cl;
	InChI InChI=1S/C19H19BrClNO2/c1-22-4-2-11-7-17(21)18(23)9-14(11)16(10-22)15-8-13(20)6-12-3-5-24-19(12)15/h6-9,16,23H,2-5,10H2,1H3/t16-/m0/s1; Key:DIKLCFJDIZFAOM-INIZCTEOSA-N;

Berupipam (INNTooltip International Nonproprietary Name; developmental code name NNC 22-0010) is a selective dopamine D₁ receptor antagonist of the benzazepine group which was under development for the treatment of psychotic disorders but was never marketed.^[1]^[2] It reached phase 1 clinical trials prior to the discontinuation of its development.^[1]

Other namesNNC 22-0010; NNC-22-0010; NNC220010; NNC2210; NNC-2210

Quick facts Clinical data, Other names ...

Close

Berupipam and closely related dopamine D₁ receptor antagonists were reported to have been generally well-tolerated in clinical trials, but side effects included restlessness, drowsiness, other central nervous system-related symptoms, and orthostatic hypotension.^[3]

Berupipam, in radiolabeled form, has been studied for use in positron emission tomography (PET) imaging.^[4]^[5]^[6] The drug was first described in the scientific literature by 1994.^[3]

See also